Drug Information

Drug (ID: DG01405) and It's Reported Resistant Information

• Name: Nimotuzumab
• Indication:
  In total 1 Indication(s)
  Head and neck cancer [ICD-11: 2D42]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Esophageal cancer [ICD-11: 2B70]; [1]
• Target: .; NOUNIPROTAC; [1]
• TTD Drug ID: D05BKS

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Esophageal cancer [ICD-11: 2B70]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Mutation; .
• Resistant Disease: Esophageal squamous cell carcinoma [ICD-11: 2B70.3]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: PI3K/AKT/mTOR signaling pathway; Activation; hsa04151
• Mechanism Description: NGS examination of this patient demonstrated that PIK3CA mutation and a RICTOR amplification might participate in primary and acquired resistance to nimotuzumab, respectively, via the PI3K/AKT/mTOR signaling pathway.

Key Molecule: Rapamycin-insensitive companion of mTOR (RICTOR) [1]

• Molecule Alteration: Structural variation; Amplification
• Resistant Disease: Esophageal squamous cell carcinoma [ICD-11: 2B70.3]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: PI3K/AKT/mTOR signaling pathway; Activation; hsa04151
• Mechanism Description: NGS examination of this patient demonstrated that PIK3CA mutation and a RICTOR amplification might participate in primary and acquired resistance to nimotuzumab, respectively, via the PI3K/AKT/mTOR signaling pathway.

References

• Ref 1: Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing .Front Oncol. 2020 Oct 29;10:574523. doi: 10.3389/fonc.2020.574523. eCollection 2020. 10.3389/fonc.2020.574523